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Synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple 
system atrophy (MSA) are characterized by pathological accumulation of α-synuclein (α-syn). Amongst 
the various approaches attempting to tackle the pathological features of synucleinopathies, antibody-
based immunotherapy holds much promise. However, the large size of antibodies and corresponding 
difficulty in crossing the blood-brain barrier has limited development in this area. To overcome this 
issue, we engineered single-chain variable fragments (scFvs) against fibrillar α-syn, a putative disease-
relevant form of α-syn. The purified scFvs showed specific activity towards α-syn fibrils and oligomers 
in comparison to monomers and recognized intracellular inclusions in human post-mortem brain tissue 
of Lewy body disease cases, but not aged controls. In vitro studies indicated scFvs inhibit the seeding 
of α-syn aggregation in a time-dependent manner, decreased α-syn seed-induced toxicity in a cell 
model of PD, and reduced the production of insoluble α-syn phosphorylated at Ser-129 (pS129-α-syn). 
These results suggest that our α-syn fibril-specific scFvs recognize α-syn pathology and can inhibit the 
aggregation of α-syn in vitro and prevent seeding-dependent toxicity. Therefore, the scFvs described 
here have considerable potential to be utilized towards immunotherapy in synucleinopathies and may 
also have applications in ante-mortem imaging modalities.
Synucleinopathies are a group of neurodegenerative disorders comprising Parkinson’s disease (PD), dementia 
with Lewy bodies (DLB), and multiple system atrophy (MSA)1. PD is clinically characterized by motor symptoms 
of bradykinesia, unsteady gait and resting tremor that precedes cognitive impairment whilst, in contrast, DLB 
manifests as a cognitive disorder that often leads to motor features2. However, despite differences in the sequence 
of clinical symptomatology, PD and DLB are both neuropathologically characterized by accumulations of the 
protein α-synuclein (α-syn) in vulnerable neurons as Lewy bodies (LBs) and in neuronal processes as Lewy 
neurites3. MSA is characterized by α-syn aggregates in oligodendroglia as Papp-Lantos bodies/glial cytoplasmic 
inclusions4, though neuronal accumulations of α-syn are also observed5.
Several lines of evidence indicate that α-syn aggregation is a critical pathogenic event in the natural history 
of Lewy body diseases. α-Syn is the major protein component of LBs, various point mutations and/or multipli-
cations in the α-syn gene have been described in familial PD, exogenous expression of α-syn in Drosophila and 
transgenic mice induce the formation of PD-like pathological phenotypes and behavior, and down-regulation of 
the α-syn protein reduces risk of developing PD6–13. Although α-syn is implicated in PD risk, it is also thought to 
have important neuronal functions as it is a relatively abundant protein, comprising 0.5–1% of the total protein 
in soluble cytosolic brain fractions14,15.
Although α-syn is a soluble, monomeric, unfolded protein, it can convert to various conformations such 
as helically folded tetramers resisting aggregation or oligomers, small aggregates, protofibrils or irreversible 
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insoluble amyloid fibrils based on the cellular environmental stimuli and genetic factors16–18. Formation of α-syn 
fibrils is a multistep reversible heterogeneous reaction that can be initiated by conversion of native soluble α-helix 
rich protein into the pathogenic β-sheet structures, utilizing small oligomers or fibrils as seeds for propagation19. 
Multiple lines of evidence suggest that the oligomeric or fibrillar form of α-syn mediates toxicity causing neu-
rodegeneration and neuronal cell-death leading to PD and other synucleinopathies20–22. Therefore, molecules 
that can detect, bind and inhibit the toxic oligomeric and fibrillar species of α-syn can be used as diagnostic and 
therapeutic tools for synucleinopathies.
Strategies involving active and passive immunizations have been shown to ameliorate the symptoms of syn-
ucleinopathies using α-syn antibodies in animal models of PD, DLB and MSA. However, the large size of mon-
oclonal antibodies, limiting their ability to cross the blood-brain barrier (BBB), are major limitations to this 
approach23. One of the applications of recombinant DNA technology is the generation of phage or yeast sur-
face display antibody libraries consisting of variable domains of heavy chain (VH)and light chain (VL) fragment 
in multiple permutation-combinations that can be used to screen for functional single-chain variable fragment 
(scFv) antibodies against any target antigen. Alternatively, already characterized functional monoclonal antibod-
ies can be sequenced and VH and VL sequences responsible for antigen binding can be identified and cloned to 
synthesize scFv gene.
ScFv is a small antigen-binding molecule, which consists of the VH and VL regions linked by a short flexible 
linker, generally (Gly4Ser)3. Additionally, scFv can be genetically engineered to include chemical tracers or a 
cell-penetrating peptide, thus raising the possibility of using these tools for biomarkers or therapeutics. Therefore, 
scFv fragments preserve the antigen-binding capacity, affinity and specificity of antibodies but with lower mass, 
better penetration in tissues, shorter half-lives and faster clearance. Moreover, as scFv lack the tail Fc region of 
antibodies that interacts with the immune system, these fragments are less likely to initiate a potentially deleteri-
ous immune response than antibodies24–29.
We previously described a conformation-specific anti-α-syn monoclonal antibody (Syn-F2) that specifically 
recognizes α-syn fibrils30,31. For our current study, using the sequence from Syn-F2, we produced scFv antibodies 
with and without a cell-penetrating peptide (CPP) using E. coli expression system. We analyzed scFvs binding to 
α-syn fibrils and oligomers and their effect on α-syn seeding induced aggregation and toxicity. We found scFvs 
to be α-syn fibril and oligomer specific in vitro and they labelled intracellular aggregates in post-mortem tissue of 
cases with Lewy body pathology. Furthermore, they were capable of inhibiting the seeding of α-syn aggregation 
in an in vitro assay, whilst reducing the toxicity caused by α-syn seeds in cell model. scFvs also blocked the aggre-
gation of α-syn as detected by decreased insoluble α-syn phosphorylated at Ser-129 (pS129-α-syn) in another 
cell model. These results suggest that α-syn pathology-specific scFvs are able to specifically bind α-syn fibrils and 
oligomers and inhibit the seeding of α-syn aggregation that might lead to the pathogenesis of PD, DLB and MSA.
Results
Generation of α-syn fibril-specific scFvs. The single-chain variable fragment (scFv) antibodies, scFv-pF 
and scFv-pC were generated by cloning DNA sequences of VL and VH domains from Syn-F2 antibody sequence in 
pET-28a expression vector. The variable domains were connected by a (Gly4Ser)3 linker sequence and a 6x-His tag 
for convenient purification and detection was added at the C-terminus. scFv-pC had a cell-penetrating peptide 
(CPP)-RQIKIWFQNRRMKWKK at its N-terminus to facilitate intracellular delivery (Fig. 1a). Protein expres-
sion vectors for scFv-pF and -pC were transformed into E. coli BL21 (DE3) cells and induction profiling was per-
formed at various IPTG concentrations. Surprisingly, higher expression of scFv-pF and -pC was observed in the 
insoluble fractions in comparison to soluble fractions. Efforts to optimize and enhance soluble expression of scFvs 
utilizing various conditions such as lower growth temperatures of 16 °C, 20 °C and 25 °C, different IPTG concen-
trations (from 0.01 mM to 1 mM), addition of various chaotropic agents e.g. sorbitol, ethanol, and L-arginine, 
were largely unsuccessful. Therefore, we decided to purify the scFvs from the insoluble fractions containing E. coli 
inclusion bodies (IBs). Expression of scFvs in the insoluble fractions was found to be highest upon induction with 
0.1 mM IPTG overnight at 25 °C (Fig. 1b). Traditional methods to dissolve IBs involve using high concentrations 
of chaotropic agents such as urea (8 M) or guanidine chloride (6 M) which lead to complete denaturation of active 
protein, rendering it unable to display antigen binding properties. High amount of urea or guanidine chloride is 
further removed from denatured proteins using extensive slow or sequential dialysis protocols which simultane-
ously refold inactive proteins to gain activity back. A mild solubilization buffer containing 50 mM Tris-HCl, and 
2 M urea at pH 12.5 was chosen to solubilize the IBs32. ScFv fragments were purified using FPLC according to the 
protocol described in methods and urea solubilization method gave a yield of ~50% as shown in (Suppl. Fig. S1a). 
Western blotting using anti-His antibody confirmed the presence of full-length scFv fragment after purification 
(Fig. 1c) and size exclusion chromatography showed that most of the purified protein is in the monomeric state 
with some dimers and tetramers which were separated and monomeric proteins were used for further experi-
ments (Fig. 1d). Protein standards of known molecular weights were run to determine the corresponding size and 
elution profile (Suppl. Fig. S1b).
scFv-pF and -pC specifically recognize α-syn fibrils and oligomers. To determine the activity and 
specificity of the purified scFvs we employed different biochemical techniques. First, we used dot blotting to 
assess the binding specificity of the purified scFvs for different forms of α-syn. For this purpose, we spotted puri-
fied α-syn monomers, dopamine-induced oligomers (DA-oligomers) and fibrils on nitrocellulose membranes 
and probed using the scFvs. It was observed that the scFvs bound with higher specificity to α-syn fibrils and 
DA-oligomers in comparison to α-syn monomers (Fig. 2a, top panel). scFv-pC had slightly better binding than 
scFv-pF since it showed binding with 250 ng α-syn fibrils compared to scFv-pF which showed binding with only 
up to 500 ng α-syn fibrils (Fig. 2a, top panel). Syn-F2 antibody was used as a positive control and Syn-1 antibody 
was used in dot blots to determine the equal loading of α-syn antigens (Fig. 2a, top panel)30. After determining 
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Figure 1. Schematic representation of the scFv-pF and scFv-pC fusion proteins, their expression and 
purification. (a) Light chain (VL) and heavy chain (VH) variable domains were linked by a (Gly4Ser)3 linker 
with a C-terminal 6xHis-tag. Amino acid number starting for each domain is marked. scFv-pC consisted of 
an N-terminal CPP sequence. (b) SDS-PAGE analysis of expression of scFv-pF and -pC in soluble/insoluble 
fractions of BL21(DE3) cells upon overnight incubation at 25 °C, induced by different IPTG concentrations. 
scFv-pF and -pC are indicated by an arrow. (c) SDS-PAGE (left) and western blot (right) analysis of His-trap 
purified and dialysed scFv-pF and -pC. Molecular masses (kDa) of protein standards are indicated on the left. 
(d) Size exclusion chromatography showing the monomeric scFv-pF and -pC, proteins as major fractions.
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Figure 2. Characterization of purified scFv-pF and scFv-pC. (a) Dot blot showing specific binding of scFv-pF and 
-pC to fibrillar and oligomeric forms of α-syn. Indicated amounts of full-length α-syn monomers (M), fibrils (F) 
or oligomers (O) (upper panel) and 1 μg of A-beta 42, Tau, IAPP (bottom panel) were spotted onto a nitrocellulose 
membrane. The membranes were probed with scFv-pF/-pC and Syn-F2 for α-syn, 82E1 for A-beta 42, 5E2 for 
Tau, R10/99 for IAPP antibodies, and Syn-1 for full-length α-syn. (b) In vitro seeding of α-syn aggregation assay 
showing inhibition by Syn-F2, scFv-pF and -pC. α-Syn monomers (25 µM) were seeded with 1 µM α-syn seeds, 
which were incubated in the presence or absence of Syn-F2 (1 µM), scFv-pF (40 µM) and scFv-pC (8 µM) for 
6 hours with continuous shaking at 37 °C. The extent of fibrillation was estimated by the Th-S fluorescence assay 
at indicated time-points. The assay was performed in triplicate (average of triplicate measurements ± standard 
deviations). Statistical analysis was performed using two-way ANOVA with Sidak’s multiple comparison test. 
(****p < 0.0001). (c) Electron microscopy images of negatively stained samples collected at time 0 and 6 hours 
from experiment in (b) show that mature amyloid fibrils (300–700 nm long) are formed in seeds and monomer 
incubated samples at 6 hours time point which is inhibited by Syn-F2, scFv-pF and scFv-pC antibodies. Arrowhead 
indicate presence of seeds at the time-point 0 and 6 hours samples. Magnification 28500x. Scale bar = 500 nm.
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the specificity of scFvs for α-syn fibrils and oligomers, we wanted to examine whether this binding is specific 
for α-syn fibrils or the scFvs can non-specifically bind to any other type of amyloid fibrils as well. Monomeric 
and fibrillar forms of various amyloidogenic-type proteins such as A-beta 42, tau, and islet amyloid polypeptide 
(IAPP) were coated and dot blots were performed. scFv-pF and -pC showed binding only with α-syn fibrils and 
not with A-beta 42, tau or IAPP proteins, confirming its specificity towards α-syn fibrils (Fig. 2a, bottom panel).
In order to further evaluate the specificity of scFvs for α-syn fibrils, we performed indirect ELISA using α-syn 
monomers and fibrils. scFvs showed high binding to α-syn fibrils compared to monomers replicating the data 
observed in dot blotting (Suppl. Fig. S2a) whereas, the control antibody, Syn-1 showed equal reactivity to both 
α-syn monomers and fibrils (Suppl. Fig. S2b). These results showed that purified scFv-pF and -pC had correctly 
folded antigen-binding sites that efficiently bound the α-syn fibrils.
scFvs inhibit seeding of α-syn aggregation in in vitro assay. Previous work had shown that amy-
loid fibrils are formed in a nucleation-dependent polymerization fashion33. Based on this model, there are three 
phases: first, a nucleation or lag phase wherein soluble species are generated via nucleation of oligomeric species; 
second, a polymerization or growth phase in which oligomeric species polymerize giving rise to fibrils; and a final 
equilibrium phase where it reaches plateau34. It has been demonstrated that small aggregates or seeds accelerate 
the nucleation phase of amyloid formation by a process called “seeding” both in vitro and in vivo35–38. According 
to established protocols, to generate α-syn “seeds”, mature α-syn fibrils were sonicated to fragment into smaller 
short fibrillar pieces (Suppl. Fig. S2c,d). The seeds were added to α-syn monomers and the mixture was incubated 
to allow the aggregation process to take place. Incubation of seeds with α-syn monomers speeded up the fibril for-
mation which was demonstrated by enhanced Th-S binding. The quantity of α-syn fibrils formed upon addition 
of seeds in the six hours duration is equivalent to α-syn fibrils formed in 72 hours without addition of seeds39,40.
Since the scFvs and Syn-F2 showed specific binding to α-syn fibrils, we evaluated whether they can prevent 
the seeding of α-syn monomers to fibrils. To determine the effect of the scFvs on the seeding of α-syn monomers, 
α-syn seeds (1 μM-minimum amount required for efficient seeding) were incubated either alone or in combi-
nation with Syn-F2 (1 μM), scFv-pF (40 μM) or scFv-pC (8 μM) for 1 hour at 37 °C with continuous shaking, 
followed by incubation with 25 μM α-syn monomers. The reaction was allowed to occur for six hours at 37 °C and 
samples were collected at every hour. α-Syn monomers or seeds alone had no appreciable change in Th-S counts 
at all time-points however samples having both α-syn monomers and seeds showed significant increase in fibril 
formation as indicated by Th-S counts (Fig. 2b) and further confirmed by electron microscopy data (Fig. 2c), 
with increasing time-points. As shown in Fig. 2b, scFv-pF and scFv-pC inhibited the seeded fibrillation of α-syn 
monomers significantly (p-values < 0.001) similar to Syn-F2, as evident by the low count of Th-S binding in the 
presence of the scFvs. Similar inhibitory results were obtained at 24 hours time-point by scFv-pF/-pC and Syn-F2 
(Suppl. Fig. S2f).
Moreover, scFvs or Syn-F2 incubated alone without seeds did not have any effect on the aggregation of α-syn 
monomers. α-Syn monomers had negligible Th-S counts indicating the absence of any fibrillary structures, which 
did not increase by Syn-F2 or scFv-pF/-pC addition (Suppl. Fig. S3a). More importantly, α-syn seeds alone, in 
the absence of α-syn monomers, incubated with Syn-F2, scFv-pF or scFv-pC had only some basal counts of 
Th-S, which was not enhanced by Syn-F2 or scFv-pF/-pC co-incubation (Suppl. Fig. S3b). The concentration 
required for the scFvs to inhibit the seeded aggregation of α-syn monomers is higher compared to Syn-F2. The 
lower affinity of these scFvs compared to Syn-F2 might possibly be the avidity effect due to the presence of only 
one antigen binding domain. Western blotting using samples from in vitro seeding of α-syn aggregation assay 
(Fig. 2b) showed inhibition of high molecular weight aggregate bands by Syn-F2, scFv-pF and -pC co-incubation 
compared to seeds and monomer alone at 6 hours time-point (Suppl. Fig. S2e).
CPP allows the transport of scFv across live cell membrane. The key challenge towards 
antibody-based therapy is effective delivery of the therapeutic bioactive molecule at the site of treatment i.e. the 
brain in the case of neurodegenerative diseases. Addition of cell permeable peptide molecules has been shown 
to facilitate delivery of target molecules to intracellular locations as well as to aid in crossing the blood-brain 
barrier (BBB)41,42. Recently, cell-penetrating peptide (CPP) has also been shown to deliver cargo molecules into 
a variety of cell systems and across the BBB41. We decided to use a 16-amino acid long CPP obtained from the 
third helix of the Antennapedia homeodomain from Drosophila in our scFv coding sequence to enable it to cross 
cell membranes29,42.
To detect if there was any favorable effect of addition of CPP in scFv sequence towards cell delivery, scFv 
without any peptide (scFv-pF) or scFv fused with CPP (scFv-pC) were incubated with human neuroblastoma 
SH-SY5Y cells or HEK293T cells in Opti-MEM media for 120 min at 37 °C. Opti-MEM media containing scFvs 
was removed, cells were extensively washed, fixed and stained using anti-His antibody to visualize scFv proteins 
using confocal microscope. Serial optical sections in the Z-axis of the cell, collected at 1 μm intervals (total thick-
ness of 10 μm) were projected as a flat single image and observed. scFv-pC showed vesicular and membranous 
pattern across multiple cells indicating binding to cell membranes as well as intracellular localization (Fig. 3b,d). 
On the other hand, scFv-pF had undetectable signals by immunofluorescence microscopy (Fig. 3a,c), confirm-
ing that scFv-pF is unable to cross the cell membrane by itself at this time-point. Further analysis of individual 
z planes using orthogonal projection along with XZ and YZ views confirmed internal localization of scFv-pC 
(Fig. 3e, right) but not for scFv-pF (Fig. 3e, left). Phalloidin-594 was used as a control to mark areas of cytoskeletal 
structure.
scFvs blocks α-syn aggregates-induced toxicity. Amyloid fibrillation is known to generate oligo-
meric/fibrillar intermediates causing cell death43–45. To analyze the ability of scFv to block α-syn-mediated cel-
lular toxicity, an MTT assay was performed using a SH-SY5Y cell model of PD as previously established45,46. In 
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living functional cells, the tetrazolium salt, MTT, gets reduced to formazan by mitochondrial dehydrogenase. 
Incubation of SH-SY5Y cells with α-syn seeds (2 μM) followed by α-syn monomers (10 μM) leads to the forma-
tion of toxic α-syn fibrils in a seeding model, thus reducing cell viability. Previous report has suggested that α-syn 
seeds-dependent toxicity is enhanced greatly by adding α-syn monomers45.
SH-SY5Y cells were treated with α-syn seeds in the presence or absence of Syn-F2, scFv-pF or scFv-pC in 
two identical sets with or without α-syn monomer addition. As shown in Fig. 4a, consistent with the role of the 
scFvs in inhibiting α-syn seeds-mediated aggregation (Fig. 2b), they also reduced the toxicity caused by α-syn 
Figure 3. Intracellular delivery of scFv by CPP in SH-SY5Y and HEK293T cells. SH-SY5Y (a,b) or HEK293T 
(c,d,e) cells incubated with scFv-pF and -pC for 120 min in Opti-MEM were fixed and stained using anti-His 
antibody and Phalloidin-594 and imaged using confocal microscope. Serial optical sections in the Z-axis of the 
cell, collected at 1 μm intervals with 63x oil immersion objective lense (NA 1.4) were projected and observed in 
a total thickness of 10 μm by using LSM 780 (version 3.2) software. scFv-pF (a or c) is not showing any specific 
staining indicating no intracellular delivery due to the lack of any cell penetrating peptide. scFv-pC (b,d) is 
showing good specific staining around the cells and inside cells indicating its binding to the cell membrane 
and possibly intracellular delivery due to the presence of CPP-peptide. (e) Merged confocal image with the 
orthogonal projection of scFv-pF (left) and scFv-pC (right) localization along with XZ and YZ views. Scale 
bars = 10 μm.
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seeds, giving rise to a significantly higher number of viable cells as detected by increased formazon absorbance 
(Fig. 4a, p-values  < (0.05–0.001)). Syn-F2 antibody was used as a positive control and it also increased cell via-
bility showing its inhibitory role in α-syn seeds- mediated toxicity (Fig. 4a). Since scFvs and Syn-F2 inhibited 
the toxicity caused by α-syn seeds with monomer addition, it demonstrated that seeded aggregation is blocked. 
Figure 4. scFv-pF and scFv-pC reduce the toxicity caused by α-syn seeds in SH-SY5Y cell model of PD. The 
viability of SH-SY5Y cells was evaluated using MTT assay (a) or LDH activity assay (b). 2 µM α-syn seeds 
were incubated with 0.25 µM Syn-F2, 0.25 µM scFv-pF, or 0.25 µM scFv-pC. After incubation, 10 µM α-syn 
monomers were then added in Opti-MEM for 48 hours prior to MTT addition. For MTT assay, the results 
are expressed as percentages of the average of the control (untreated cells). For LDH assay (b) 50 μl media 
was removed before the addition of MTT reagent and released LDH activity was measured. The absorbance 
was measured and percentage of the viable cells or LDH activity was plotted (average of 3 wells ± standard 
deviation). Statistical analysis was performed using one-way ANOVA with Dunnet’s multiple comparison test. 
(***p < 0.001; **p < 0.01; *p < 0.05).
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However, scFvs and Syn-F2 co-incubation with α-syn seeds without monomer addition also reduced the toxicity 
indicating that these antibodies inhibits its internalization as well as further seeded aggregation. These results 
were also confirmed by measuring the activity of released LDH in the media (Fig. 4b). In any case, aggregation 
is not completely inhibited by scFvs and Syn-F2 perhaps due to the secondary mechanisms employed by α-syn 
seeds and monomers once inside the cells to cause toxicity, such as interactions with mitochondrial membranes47.
scFvs reduce insoluble pSer129 α-syn level in cell model. α-Syn has been found to be modified 
by a variety of post-translational modifications such as phosphorylation, acetylation, nitration, glycosylation, 
SUMO-ylation and ubiquitination48–55. However, the exact role of these modifications in α-syn functional reg-
ulation or with respect to the role of α-syn in PD pathogenesis is not clear. pS129-α-syn is the most abundant 
post-translational modification shown in LBs48. ~90% of aggregated α-syn in LBs is pS129-α-syn compared to 
only ~4% α-syn in normal cellular conditions56. Such abundance of pS129-α-syn implicates an important role 
of phosphorylation in α-syn aggregation and pathogenesis of PD. Recent reports have shown that pS129-α-syn 
may play a critical role in speeding PD pathogenesis by decreasing affinity of pS129-α-syn to membranes, thereby 
enhancing its aggregation57.
Previous work in our laboratory as well as by other groups has shown that α-syn seeds when incubated 
with α-syn monomers lead to the formation of fibrils and enhance aggregation45. We developed HEK293T cell 
model wherein exogenous α-syn expression recapitulates the aggregation induction upon α-syn seeds addition. 
Immunocytochemistry data (Suppl. Fig. S6) showed that α-syn expression in presence of seeds lead to the for-
mation of insoluble aggregates as detected by pSer129 staining. Effect of antibodies on α-syn expression, aggre-
gation and phosphorylation can be tested after seeds internalization by adding them in cell-culture media. This 
aggregated α-syn is detected by enhanced levels of insoluble pSer129 α-syn. α-Syn exogenous wild-type plasmid 
expression alone showed the presence of a basal level of phosphorylated α-syn in the soluble fraction (due to 
the overexpression of α-syn); however, there was no phosphorylated α-syn in the insoluble fraction (Fig. 5a). 
Addition of α-syn seeds alone did not show any phosphorylated or non-phosphorylated α-syn protein (Fig. 5a). 
We asked whether Syn-F2 or scFvs can decrease insoluble pSer129 α-syn in this cell model and observed that 
both scFvs significantly reduce levels of pSer129 α-syn in the soluble and insoluble fractions (Fig. 5b, p < 0.001). 
On the other hand Syn-F2 had marginal effect in reducing the level of pSer129 α-syn in the soluble and insoluble 
fractions (Fig. 5a, p < 0.05). We also verified the presence of total α-syn by western blotting using pan-α-syn 
antibody, Syn-1. Quantification of the western blot results from three independent experiments showed that 
there was a significant decrease in insoluble pS129-α-syn (normalized to β-Actin and Syn-1 protein levels) fol-
lowing addition of scFv-pF and scFv-pC (Fig. 5b, p < 0.01, Suppl Fig S5c,d). Quantification of Syn-1 densitometry 
showed that scFvs treatment also reduced α-syn protein level which might be due to binding of scFvs with the 
early intermediate of α-syn fibril formation and those being cleared by cellular machinery (Suppl. Fig. S5a,b).
Based on the data obtained in Fig. 5, scFv-pF as well as scFv-pC both inhibited pSer129 α-syn levels dras-
tically compared to Syn-F2. We speculate that it might be that scFvs with their small size can also bind aggre-
gates that IgG cannot recognize. We decided to gain more knowledge about the mechanism of scFvs in reducing 
levels of pSer129 α-syn, whether it is due to engagement of scFvs with α-syn seeds exclusively extracellular or 
is there any intracellular contribution as well. We performed a time-course experiment wherein we incubated 
scFv proteins (scFv-pF/-pC) with SH-SY5Y cells for 30 min, 2 hours, 6 hours and 24 hours, fixed and stained 
using anti-His antibody and scFv proteins were visualized using wide-field microscope (Suppl. Fig. S4). scFv-pC 
showed efficient binding to cell membranes and intracellular delivery at all time-points from 30 minutes to 
24 hours whereas scFv-pF did not show any specific staining pattern at initial time-points of 30 min and 2 hours, 
however at later time points of 6 hours and 24 hours it started showing cell membrane binding (Suppl. Fig. S4). 
Since scFvs are smaller molecules (~35k Da) compared to full-length IgG molecules (150 kDa), it is highly proba-
ble that scFvs can bind to cell membrane, get internalized and, once inside the cells, can mediate effects based on 
its antibody-like properties.
scFvs detect intracellular inclusions in human brain tissues from PD and DLB patients. To 
confirm whether scFvs recognized relevant protein aggregates in human brain tissue, we used formalin-fixed 
paraffin-embedded post-mortem brain tissue from individuals with clinical and neuropathological diagnoses of 
PD (N = 1) and DLB (N = 1), in comparison to aged controls without α-syn pathology (N = 2). Staining with 
scFvs using immunohistochemistry in substantia nigra demonstrated faint background staining in control cases 
that could be native α-syn whilst diffuse granular deposits were observed in nigral neurons in PD and DLB cases 
that were not observed within control cases (Fig. 6).
Discussion
Current therapies for the synucleinopathies are symptomatic in nature and lack any significant disease-modifying 
effect. Therefore, the development of novel and effective therapies to arrest or ameliorate the progression of synu-
cleinopathies is a pressing therapeutic priority. As the aggregation of α-syn is thought to be a critical pathogenic 
event in the natural history of synucleinopathies46,58,59, many candidate therapeutics in current development aim 
to target and inhibit this process.
Naturally occurring antibodies, C-terminal targeting antibodies and conformation-specific antibodies against 
α-syn aggregates ameliorate the disease-related phenotype of mouse models, with some already in different stages 
of human clinical trials31,60,61. However, a major limitation of antibody-based therapeutics is the large size of anti-
bodies, limiting permeability to the blood-brain barrier, and often necessitating infusion directly onto the brain, 
an invasive procedure with increased risk of cerebral infection62.
With the advent of recombinant DNA technology, scFv can be designed by fusing variable regions of heavy 
and light chain with a polypeptide linker using already characterized monoclonal antibody derived sequences23. 
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Figure 5. Syn-F2, scFv-pF and scFv-pC decrease insoluble α-syn level in HEK293T cell model of PD. HEK293T 
cells were transfected with wild type α-syn plasmid using lipofectamine 3000 reagent. One group of α-syn 
plasmid expressing HEK293T cells was similarly transfected again with 0.2 µM α-syn seeds the following day 
and then incubated with 0.25 µM Syn-F2 (panel a), 0.25 µM scFv-pF (panel b), or 0.25 µM scFv-pC (panel b) for 
next 48 hours. Triton X-100 soluble (soluble fraction) and SDS-soluble (insoluble fraction) protein extracts were 
prepared, and presence of pSer129 α-syn and total α-syn was detected using anti-phospho-α-syn and Syn-1 
(stripped blot) antibodies by western blotting sequentially. In (b) ** denotes non-specific bands in insoluble 
fraction and specific band of α-syn is marked by arrow. β-Actin was used as a loading control and detected by anti-
β-actin antibody (stripped blot). Images from the same blot was cropped to show anti-phospho-α-syn, Syn-1 and 
β-actin separately. Full blot scans can be found in supplementary data file. The experiment was repeated three times 
and intensity of pSer129 α-syn bands was normalized to β-actin and Syn-1 and plotted. Statistical analysis was 
performed using one-way ANOVA with Dunnet’s multiple comparison test. (***p < 0.001; **p < 0.01; *p < 0.05).
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Critically, scFvs are considerably smaller than antibodies, enabling improved permeability to the blood-brain bar-
rier, enabling ready application at peripheral sites with improved efficiency of passage to the central nervous 
system in therapeutically meaningful doses. scFvs are believed to show similar binding affinity and specific-
ity compared to antibodies due to maintenance of similar antigenic binding sequence as the parent antibody. 
Moreover, scFv sequence can be modified to enhance affinity, avidity or intracellular targeting23,42,63. By screening 
various phage and yeast surface display libraries, some α-syn conformation-specific scFvs have been developed, 
and shown to affect different steps of α-syn aggregate formation and/or ameliorate α-syn neuropathology in 
different in vitro and in vivo model systems25–27,29,64–66. However, to the best of our knowledge, the scFvs reported 
in this study are the first of its kind based on a well-characterized conformation-specific monoclonal antibody, 
the Syn-F2 sequence30.
Our findings with our novel scFvs demonstrate, for the first time, that scFvs can employ well-validated 
conformation-specific sequences from antibodies, and use these for potential therapeutic applications. Our scFvs 
recognize α-syn fibrils specifically, and identify disease-specific intracellular accumulations in post-mortem brain 
tissue that are not observed in aged control cases. Finally, scFvs rescue cells from α-syn-mediated cellular aggre-
gation and toxicity in vitro. Taken together, our findings suggest scFvs may be a viable therapeutic option for the 
treatment of synucleinopathies. By linking to tracer compounds scFvs can also be developed as attractive target 
to be used in in vivo imaging applications as diagnostic tool towards synucleinopathies23,63,67,68. Future studies 
should aim to analyze the effect of the scFvs in other in vivo and animal models of synucleinopathies, which will 
provide important insights into safety and tolerability in intact organisms, in addition to the α-syn aggregation 
blocking properties of this class of scFv.
In conclusion, we have generated α-syn pathology-specific scFvs that can modulate α-syn aggregation 
indicating its therapeutic and diagnostic use in synucleinopathies. Given that α-syn aggregation is the neuro-
pathological hallmark of Lewy body diseases and is thought to be central to the disease process, scFvs targeting 
disease-relevant conformations have considerable potential in the search for novel therapeutics to attenuate α-syn 
aggregation.
Materials and Methods
cloning E.coli expression constructs. Sequences of the VL and VH regions from Syn-F2 were obtained 
using GenScript antibody sequencing service, and used to generate scFv construct in pET22b(+)vector. The 
construct consisted of the VL and VH regions linked by a (Gly4Ser)3 linker and a C-terminal 6x-His tag for con-
venient purification. For cloning new-constructs, forward (32 bp) and reverse primers (30 bp) were designed 
corresponding to the VL and VH sequence of Syn-F2 respectively. To add cell-penetrating peptide (CPP) to the 
scFv expression vector, another forward primer was designed containing the nucleotide sequence coding for 
CPP-amino acids - RQIKIWFQNRRMKWKK at the starting of the forward primer. Using the pET22b(+) vector 
containing the coding sequence for our scFv as a template and the newly designed forward and reverse primers, 
PCR was performed to amplify the scFv total coding sequence. The identity of the final constructs scFv-pC (with 
CPP) and scFv-pF (without CPP) was confirmed by DNA sequencing (Suppl. Fig. S7).
Expression and purification of scFvs. The scFv-pF and scFv-pC constructs in pET28a vector were trans-
formed by heat shock into E.coli BL21(DE3) bacteria for protein expression. scFv expression was induced by 
adding 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and the culture was grown overnight at 25 °C. 
The pellet was resuspended in lysis buffer containing 50 mM Tris pH 8.0, 150 mM NaCl, 10% glycerol, 1X protease 
inhibitor, 1 mM PMSF, 20 U/ml DNAse, and 10 mM MgCl2 and sonication cycles of 10 sec upto 5 min with 30 sec 
Figure 6. Immunohistochemistry data using human post-mortem brain tissues shows disease specific 
cytoplasmic granules detected by scFv-pF and scFv-pC. Staining with scFv-pF and scFv-pC in substantia 
nigra demonstrated an absence of staining in nigral neurons (a,d), whilst PD (b,e) and DLB (c,f) had granular 
intracytoplasmic deposits that were immunoreactive for both scFvs. Scale bars = 20 µm.
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on ice were done at 30 amplitude. For purification from inclusion bodies, the pellet was washed 5 times with 
50 mM Tris-HCl pH 8.0, 100 mM NaCl, 1% triton X-100, 1 M urea buffer and once with 1X PBS. The pure inclu-
sion body pellet obtained was dissolved in 100 mM Tris-HCl, 2 M urea, pH 12.5 buffer. The supernatant was puri-
fied by Ni-NTA affinity chromatography (GE Healthcare) with the addition of linear refolding gradient wherein 
a linear gradient of 2 M urea to no urea was performed to refold the denatured bound protein via a process called 
“on-column refolding”. After refolding, the non-specific bound proteins were washed extensively using 40 mM 
imidazole and our His-tagged protein was eluted using 250 mM imidazole. Overnight dialysis using 1xPBS was 
performed at 4 °C to remove imidazole from the obtained protein solution. BCA assay was performed to estimate 
protein concentration and purified protein was frozen in small aliquots at −80 °C.
Western blot. The samples were boiled with 5X SDS-lamelli sample buffer and separated on 12% SDS-PAGE 
gel. Proteins were transferred to nitrocellulose membrane and developed using anti-6X-His tag mouse antibody 
(1:2500, Abcam) followed by incubation with HRP-conjugated IgG goat anti-mouse antibody (Thermo Scientific) 
at a dilution of 1:10,000 using SuperSignal West-Pico -Chemiluminescent Substrate. All blots were imaged in 
Bio-Rad ChemiDoc MP imaging system.
Preparation of α-syn monomers, oligomers, fibrils and seeds. The different forms of α-syn were 
prepared as described previously40. Briefly, for preparation of α-syn fibrils, 25 μM of α-syn samples were aged in 
PBS for 5 days at 37 °C with continuous shaking at 800 rpm. The formation of α-syn fibrils was monitored by Th-S 
fluorescence assay. Oligomers were prepared according to previously published protocol69. α-Syn seeds were gen-
erated by fragmenting mature α-syn fibrils through sonication. To prepare monomers, α-syn was passed through 
a 100 kDa molecular weight cut-off (MWCO) filter to get rid of high molecular aggregates.
Dot blot. Nitrocellulose-membrane was spotted with 5 µl/spot of monomeric and aggregated forms of α-syn, 
A-beta 42, tau and islet amyloid polypeptide (IAPP) proteins. The samples were dried for 30 min followed by 
blocking in 5% skimmed milk (in PBST). The membranes were incubated overnight at 4 °C with scFv-pF (5 µg/
mL) or scFv-pC (5 µg/mL) or respective control antibodies: Syn-1 (for α-syn, BD Biosciences, 50 ng/ml); 82E1 
(for A-beta, IBL America, 50 ng/ml); 5E2 (for Tau, kindly provided by Prof. Dominic Walsh, Harvard Medical 
School, 50 ng/ml); and R10/99 (for IAPP, Santa Cruz Biotechnology 100 ng/ml). Post incubation the blots were 
developed similar to western blot.
Indirect enzyme-linked immunosorbent assay (ELISA). A 96-well clear MaxiSorp plate (Nunc) was 
coated with 100 ng/100 µL (per well) of α-syn monomers and fibrils in PBS, incubated overnight at 4 °C. After 
blocking (5% milk in PBST), 500 ng, 250 ng, and 50 ng of scFv-pF and scFv-pC were dispensed in the wells and 
incubated for 2 hours at 37 °C. The plate was incubated with Anti-6x his antibody (1:2000) and goat anti-mouse 
secondary antibody (1:3000) and developed with 50 µl/well of TMB substrate (KPL) for 10–30 min. The absorb-
ance was measured at 450 nm using a Perkin-Elmer atomic absorption spectrometer.
Immunohistochemistry. Post-mortem brain tissues were obtained from Newcastle Brain Tissue Resource, 
Institute of Neuroscience, Newcastle University, UK. Fixed midbrain tissue from a PD case, a DLB case and two 
aged controls were stained with scFv-pF and -pC. Following dewaxing and epitope unmasking using citrate pH 6 
and formic acid, sections were incubated in scFvs (both diluted 1:2 in PBS) for one hour at room temperature. To 
identify scFv binding, we used anti-6xHis antibody (ab18184, Abcam, Cambridge, UK; 0.5 mg/ml) for one hour 
at room temperature. Primary antibody binding was then visualized with Menarini MenaPath kits (Menarini 
Diagnostics, UK) according to manufacturer’s instructions, and utilizing the MenaPath Purple chromagen to 
enable differentiation of antibody binding compared to neuromelanin, and counterstained with haematoxylin. 
Donors or next of kin provided informed consent to donate tissues. All procedures were approved according to 
the Newcastle Brain Tissue Resource Ethics Committee and the local UK National Health Service Research Ethics 
Committee. All methods involving human post-mortem brain tissues were performed based on the guidelines of 
Newcastle Brain Tissue Resource Ethics Committee and the local UK National Health Service Research Ethics 
Committee.
Thioflavin-S (Th-S) aggregation assay. α-syn seeds were incubated in PBS either alone (1 µM), or in 
combination with scFv-pF (40 µM), scFv-pC (8 µM) or Syn-F2 (1 µM), in sealed 1.5 mL sterile polypropylene 
tubes for 1 hour at 37 °C with continuous shaking at 300 rpm in a total volume of 100 µL. 25 µM α-syn monomers 
were added in PBS at a final volume of 500 µL, and the reaction mixture was incubated at 37 °C with continuous 
shaking at 300 rpm. Aliquots were collected at 1 hour intervals between 0–6 hours and were flash frozen using 
liquid nitrogen. The aggregation of α-syn was assessed using Th-S fluorescence assay. 10 µL of each sample was 
mixed with 40 µL of Th-S reagent (25 µM) in PBS. Fluorescence was measured in a 384-well, non-treated, black 
micro-well plate (Nunc) using a Perkin Elmer EnVision Multimode Plate Reader with excitation and emission 
wavelengths of 450 nm and 486 nm, respectively.
Transmission electron microscopy. The samples (5ul) were deposited on Formvar-coated 400-mesh cop-
per grids (Agar Scientific, UK), fixed briefly with 0.5% glutaraldehyde, washed with dd water, negatively stained 
with 2% uranyl acetate (Sigma) and imaged with a FEI Talos F200C TEM electron microscope at 200 keV.
Cell culture. Human embryonic kidney (HEK293T) cells and human neuroblastoma SH-SY5Y cells were 
cultured according to ATCC protocols in culture media at 37 °C in a 5% CO2 atmosphere.
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Immunofluorescence. SH-SY5Y or HEK293T cells were plated at a density of 150,000 cells on poly-L-lysine 
coated coverslips and next day incubated with scFv-pF or -pC at 2 μg/ml concentration for different time-points 
such as 30 min, 2 hours, 6 hours or 24 hours in Opti-MEM media, washed three times with 1X PBS and fixed in 
4% PFA for 20 min, permeabilized with 0.5% Triton-X 100 for 5 min and stained using anti-His antibody (1:500, 
Abcam), Phalloidin-594 (1:100, Thermo Scientific), and anti-Ms-Alexa-488 (Thermo Scientific). Stained cover-
slips were visualized using 63X objective with Carl Zeiss wide field upright microscope or confocal microscope. 
Final images were assembled using Adobe Photoshop software.
MTT and LDH activity assay. SH-SY5Y cells were plated at a density of 15,000 cells/well in 96-well plate 
(Nunc), and incubated for 24 hours. 2 µM α-syn pure seeds were incubated alone or with either 0.25 µM Syn-F2, 
0.25 µM scFv-pF, or 0.25 µM scFv-pC in 100 µL Opti-MEM for 30 min at 37 °C at 300 rpm shaking. The media 
was replaced with the 100 µL Opti-MEM containing desired seeds or seeds plus antibodies in two sets. After 
1 hour, 10 µM α-syn monomers were added in another 100 µL Opti-MEM to the cells in one set or only 100 µL 
Opti-MEM was added, and incubated for 48 hours. Control wells consisted of Opti-MEM only with no treatment, 
and blank wells consisted of no cells. For LDH activity assay 50 μl media was removed before the addition of MTT 
reagent. 20 µL of 6 mg/mL MTT in PBS was added to each well, and the plate was incubated at 37 °C for 4.5 hours. 
The medium-MTT solution was removed and 100 µL/well of 15% (w/v) SDS, 50% (v/v) N,N-dimethylformamide, 
pH 4.7, was added and the plate was incubated overnight at 37 °C. The absorbance was measured at 590 nm using 
Nano Quant by TECAN. LDH activity was spectrophotometrically measured at 490–620 nm using a Pierce LDH 
Cytotoxicity Assay kit (Thermo scientific) according to the manufacturer’s indications using 50 μl media from 
treated cells. LDH activity from total cells lysates with media was defined as the sum of intracellular and extracel-
lular LDH activity, normalized as 100% and then, the amount of LDH released to the extracellular medium was 
expressed as percentage of this total value in all the other samples.
Detection of insoluble pS129-α-syn in HEK293T cell model of PD. HEK293T cells in cDMEM were 
plated at a density of 800,000 cells (2 mL/well) in a 6-well plate, and incubated for 24 hours. The cells were trans-
fected with 2 µg/well of wild-type α-syn plasmid in Opti-MEM using lipofectamine 3000 transfection reagent 
(Invitrogen) according to manufacturer’s protocol. Four hours after incubation with the transfection mixture, 
complete DMEM was added to the cells and incubated for 24 hours. The cells were transfected with 0.2 µM pure 
α-syn seeds similarly and after 4 hours, the cells were either treated with 0.25 µM Syn-F2, 0.25 µM scFv-pF or 
0.25 µM scFv-pC for 48 hours. The control wells consisted of Opti-MEM only with no treatment. After 48 hours, 
triton X-100 soluble (soluble fraction) and SDS-soluble (insoluble fraction) lysates were prepared and quantified 
using Thermo-Scientific Micro-BCA Protein Assay Kit for equal loading on SDS-PAGE. Western-blotting was 
performed to detect the phosphorylated α-syn using anti-α-syn (phospho S129) antibody (ab51253, 1:2000) and 
the total α-syn using Syn-1 antibody (BD Biosciences, 100 ng/mL). Anti-β-actin antibody (C4) Sc-47778 was 
used as the loading control. ImageJ was used for quantification.
Ethical agreements. Donors or next of kin provided informed consent to donate tissue. All procedures were 
approved and performed according to the local UK National Health Service Research Ethics Committee.
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